Stop Pancreatic Cancer Before It Goes Toxic

Recommend to others!

Recent blood test studies prove that now it is possible to detect and diagnose the premature deadly pancreatic cancer. When the researchers reported at the Yearly Gastrointestinal Cancer Symposium, they said that the test, which can easily measure the levels of proteins called the PAM4, has the ability to identify pancreatic cancer at a premature stage of the ailment. Premature pancreatic cancers generally fly underneath the radar thereby causing no single symptom. They usually go undetected till the time they have multiplied. This to some extent accounts for the dismal prognosis which is then suffered by most individuals diagnosed with this illness. It is therefore that any means of detection of premature pancreatic cancer tends to be critical. As per the researchers, very normal cell has a protein which is PAM4. This gets elevated in the cancerous cells.

According to, The American Cancer Society’s most recent estimates for pancreatic cancer in the United States are for 2011:

  • About 44,030 new cases of pancreatic cancer
  • About 37,660 deaths from pancreatic cancer

The lifetime risk of having pancreatic cancer is about 1 in 71. It is about the same for both men and women. A person’s risk may be changed by certain risk factors

When an individual comes under the influence of cancer, PAM4 spills out into his bloodstream, as explained by Dr. Igor Astsaturov, who is an associate professor specializing in medical oncology. Since he was not engaged with the study he said that the results were just like “welcoming news”. The researchers then combined PAM4 with some another test CA19-9. This test is by now approved to scrutinize the pancreatic cancer during the treatment, but the combination proved even much stronger findings. It correctly identified about 85% of the patients with pancreatic cancer.

For the individuals who care for the patients with pancreatic cancer, might have the inability to spot cancer in some stages, this test has shown tremendous promise adding to their ability in diagnosing pancreatic cancer at earlier stages. The recent study updates the consequences by including the blood samples from about 300 people who were up to that time diagnosed with PDAC (pancreatic ductal adenoma carcinoma), 99 were diagnosed with other form of cancer, 126 with non cancerous pancreatic disease while 79 people with healthy controls. The researchers also stressed that the test did not emerge helpful in spotting other kinds of pancreatic cancer.

The data which is presented at the medical meetings was generally considered to be preliminary until it got published in the peer review medical journals.



Speak Your Mind


Current day month ye@r *